Figure 1 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

Generation of a collection of PMP-PDO, PDX, and PDXO models. A, Design showing the generation of PDO from tumor tissues of patients with PMP. B, Pictures of PMP-PDO models after 7 days in culture (PMP18.3, left image and PMP21.5, right image). Scale bar, 500 μm. C, Expansion of PMP-PDO models after dissociation with TrypLE Express reagent at day 2 (left) and day 7 (right; PMP5.2). Scale bar, 500 μm D, Design showing the generation of PDX and PDXO from tumor tissues of patients with PMP. PM, Peritoneal metastases. E–G, Macroscopic images from an orthotopic PMP-PDX (oPDX) models in mice derived from low-grade G1 (E and F; PMP3.1) or high-grade G3 (G; PMP5.1) samples from patients with mucinous carcinoma peritonei. Tumor mass is indicated by red arrows. H and I, H&E staining from low-grade G1 (H; PMP3.1) and high-grade G3 (I; PMP5.1) samples from patients with mucinous carcinoma peritonei and associated oPDXs. Scale bar, 2.5 mm and 100 μm. J, H&E staining from a subcutaneous PMP-PDX (sPDX) model derived from the sample from patient with high-grade G3 mucinous carcinoma peritonei (PMP5.1). Scale bar, 2.5 mm and 100 μm. (A and D, Created with BioRender.com.). PMP, Pseudomyxoma peritonei.